Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
54 working days (255)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
KEYTRUDA (powder for injection, concentrated solution for injection), in combination with lenvatinib, is now also indicated for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. This indication was approved via the provisional approval pathway, based on objective response rate and duration of response in a single-arm trial. Full registration for this indication depends on verification and description of clinical benefit in confirmatory trials.
Registration process
Provisional registration
Involves early access to vital and life-saving medicines through time-limited registration